Treatment results of patients treated according HOVON-29 and HOVON-42 protocol
| . | Cytogenetic risk group . | Total, no. (%) . | ||
|---|---|---|---|---|
| Favorable, no. (%) . | Intermediate, no. (%) . | Unfavorable/very unfavorable, no. (%) . | ||
| Patients entered for induction, n | 233 | 1437 | 347 | 2017 |
| In CR after cycle 2 | 205 (88) | 1134 (79) | 193 (56) | 1532 (76) |
| Not randomized | ||||
| No consolidation | 30 (15)* | 166 (15)* | 33 (17)* | 229 (15)* |
| Consolidation | — | — | 353 (23) | |
| Chemotherapy cycle 3 | 116 (57) | 215 (19) | 22 (11) | 24 (2) |
| ASCT | 3 (1) | 20 (2) | 1 (1) | 409 (27) |
| Allogeneic SCT | 17 (8) | 308 (27) | 84 (44) | — |
| Randomized for consolidation | ||||
| Chemotherapy cycle 3 | 21 (10) | 210 (19) | 28 (15) | 259 (17) |
| ASCT | 18 (9) | 215 (19) | 25 (13) | 258 (17) |
| . | Cytogenetic risk group . | Total, no. (%) . | ||
|---|---|---|---|---|
| Favorable, no. (%) . | Intermediate, no. (%) . | Unfavorable/very unfavorable, no. (%) . | ||
| Patients entered for induction, n | 233 | 1437 | 347 | 2017 |
| In CR after cycle 2 | 205 (88) | 1134 (79) | 193 (56) | 1532 (76) |
| Not randomized | ||||
| No consolidation | 30 (15)* | 166 (15)* | 33 (17)* | 229 (15)* |
| Consolidation | — | — | 353 (23) | |
| Chemotherapy cycle 3 | 116 (57) | 215 (19) | 22 (11) | 24 (2) |
| ASCT | 3 (1) | 20 (2) | 1 (1) | 409 (27) |
| Allogeneic SCT | 17 (8) | 308 (27) | 84 (44) | — |
| Randomized for consolidation | ||||
| Chemotherapy cycle 3 | 21 (10) | 210 (19) | 28 (15) | 259 (17) |
| ASCT | 18 (9) | 215 (19) | 25 (13) | 258 (17) |
AML of favorable risk had core-binding factor abnormalities: t(8;21) (q22;q22), inv(16)(p13.1;q22), or t(16;16)(p13.1;q22).
The “very unfavorable” risk category had a monosomal karyotype as defined.16,17
The unfavorable risk AMLs were those without a monosomal karyotype or core-binding abnormalities, but with complex abnormalities,15 t(6;9), t(11,19), t(9;22), 11q23.3q, inv(3),5q−,7q−, −5, or −7.
AML without cytogenetic abnormalities or with loss of an X or Y chromosome as the only abnormality were classified as “normal cytogenetics” (“CN”) and AML with any other cytogenetic abnormalities were classified as “CA rest.”
CN and CA-rest were considered as intermediate risk.
— indicates not applicable.
Remaining percentages refer to percentage of patients in CR after cycle 2.